Peptide Phase 1 Licensing Benchmarks
Deal economics across 9 transactions with 9 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$113M
9 deals with terms
Median Total Value
$1.4B
Upfront + milestones
Royalty Range
6%--13%
Average low--high
Deal Count
9
2020--2025
The median upfront payment for phase 1 peptide licensing deals is $113M, based on 9 deals with disclosed terms from 2020--2025. Total deal values (including milestones) reach a median of $1.4B. Royalty rates typically range from 6% to 13%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| United Laboratories | Novo Nordisk | 2025 | $200M | $2.0B |
| Nurix Therapeutics | Biogen | 2020 | $185M | $1.9B |
| iTeos Therapeutics | Amgen | 2021 | $173M | $2.1B |
Showing 3 of 9 deals with disclosed terms. Full comp set available in the report.
Full Peptide phase-1 Comp Set
Get the complete analysis -- 9 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific peptide asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2020--2025). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.